KRAS and neoplasm: In preclinical studies using mouse models, sotorasib, in addition to directly inhibiting KRAS, has been found to inhibit the phosphorylation of ERK (extracellular signal-regulated kinase), leading to complete tumor regression in KRASG12C-mutant cancers.10,223